Bruker Acquires MSI Company SCiLS
Bruker (Bremen, Germany) has announced the acquisition of SCiLS GmbH in Bremen, Germany. Founded as a spin‑off from the University of Bremen, SCiLS develops software tools such as statistical analysis software, sophisticated visualization viewers, and secure cloud-based services for collaborative interpretation of complex mass spectrometry imaging (MSI) data sets. Currently, 95% of all MSI data is acquired by label-free MALDI imaging systems.
Bruker (Bremen, Germany) has announced the acquisition of SCiLS GmbH in Bremen, Germany. Founded as a spinâoff from the University of Bremen, SCiLS develops software tools such as statistical analysis software, sophisticated visualization viewers, and secure cloud-based services for collaborative interpretation of complex mass spectrometry imaging (MSI) data sets. Currently, 95% of all MSI data is acquired by label-free MALDI imaging systems.
Peter Maass, Theodore Alexandrov, and Dennis Trede, the founders of SCiLS, commented: “We are very pleased by the evolution of SCiLS, and now that SCiLS is a part of Bruker’s global infrastructure it will make mass spec-based imaging more accessible. As MSI is rapidly advancing in multiple application areas, we believe SCiLS has set the stage for becoming the de facto standard for mass spectrometry imaging software.”
Rohan Thakur, Executive Vice President at Bruker Daltonics, added: “Our goal is to advance the MSI field and enable a deeper understanding of the spatial distribution of various molecules in the disciplines of biomarker discovery, pharma drug tissue distribution studies, all the way to translational research in anatomical pathology and future diagnostic applications.”
For more information, please visit: www.bruker.com
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
